Drug Trial Radar · NCT07947173
Phase 1 Trial to Assess Safety and Immunogenicity of Self-replicating RNA (srRNA) Herpes Zoster Vaccine (JCXH-105)
Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
72
Planned (sponsor's estimate)
Start
Nov 2026
Primary completion
Mar 2028
Study completion Mar 2028
Sponsor
- Lead sponsor
- Immorna Biotherapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Nov 18, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 40 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Herpes zoster is caused by reactivation of varicella zoster virus. This is a Phase 1 clinical trial to evaluate the safety and immunogenicity of self-replicating RNA (srRNA) herpes zoster vaccine JCXH-105. Eligible participants will receive 2 doses of study vaccine/placebo at planned dose levels and follow scheduled safety and immunogenicity follow-up visits. The goal of this study is to assess the safety profile and immune response induced by JCXH-105.
Conditions
- Herpes Zoster (HZ)
Interventions
JCXH-105Biological
Self-replicating RNA (srRNA) Herpes Zoster Vaccine (JCXH-105)
PlaceboDrug
Placebo (sodium chloride injection) as control
Primary outcomes
What the sponsor says the trial is designed to measure.
- Serious adverse events (SAEs)Time frame: From Day 1 post- administration through 360 days after the full-course vaccination
- Solicited local injection site adverse eventsTime frame: Within 14 days after each dose of investigational vaccine/placebo
- Solicited systemic adverse eventsTime frame: Within 14 days after each dose of the investigational vaccine/placebo
- Unsolicited AEsTime frame: Within 30 days after each dose of the investigational vaccine/placebo
- Laboratory parametersTime frame: On the third day after each dose of the investigational vaccine/placebo
- Adverse events of special interest (AESIs)Time frame: From Day 1 post administration through 360 days after the full-course vaccination
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.